Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease

Dupilumab is a novel anti–IL-4 receptor-α mAb that targets the signaling pathways of IL-4 and IL-13. Thus far, the data about adequate humoral immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients who are taking dupilumab have been limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Abadeh, Armin, Lee, Jason Kihyuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598042/
https://www.ncbi.nlm.nih.gov/pubmed/36313899
http://dx.doi.org/10.1016/j.jacig.2022.08.007
_version_ 1784816233999237120
author Abadeh, Armin
Lee, Jason Kihyuk
author_facet Abadeh, Armin
Lee, Jason Kihyuk
author_sort Abadeh, Armin
collection PubMed
description Dupilumab is a novel anti–IL-4 receptor-α mAb that targets the signaling pathways of IL-4 and IL-13. Thus far, the data about adequate humoral immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients who are taking dupilumab have been limited.
format Online
Article
Text
id pubmed-9598042
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95980422022-10-26 Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease Abadeh, Armin Lee, Jason Kihyuk J Allergy Clin Immunol Glob Case Report Dupilumab is a novel anti–IL-4 receptor-α mAb that targets the signaling pathways of IL-4 and IL-13. Thus far, the data about adequate humoral immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients who are taking dupilumab have been limited. Elsevier 2022-10-26 /pmc/articles/PMC9598042/ /pubmed/36313899 http://dx.doi.org/10.1016/j.jacig.2022.08.007 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Abadeh, Armin
Lee, Jason Kihyuk
Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease
title Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease
title_full Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease
title_fullStr Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease
title_full_unstemmed Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease
title_short Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease
title_sort reduced covid-19 vaccine response in patient treated with dupilumab for igg4-related disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598042/
https://www.ncbi.nlm.nih.gov/pubmed/36313899
http://dx.doi.org/10.1016/j.jacig.2022.08.007
work_keys_str_mv AT abadeharmin reducedcovid19vaccineresponseinpatienttreatedwithdupilumabforigg4relateddisease
AT leejasonkihyuk reducedcovid19vaccineresponseinpatienttreatedwithdupilumabforigg4relateddisease

Ejemplares similares